Moderna Jumps 175% in Q3 on Cancer Therapy Trial Win, Nasdaq 100 Entry

Insider Monkey··US·Read original
3▲2 ▼0Impact / 5
Summary · why it matters

Moderna Inc. ranked as the second top-performing stock in the US market in the third quarter, with shares surging 174.98 percent over the three months ending September. The rally was driven by news that its Intismeran Autogene combined with Merck's Keytruda achieved the primary endpoint of recurrence-free survival and the secondary target of distant metastasis-free survival in a late-stage clinical trial, marking the first positive readout from a phase 3 trial combining an mRNA-based cancer treatment with individualized neoantigen therapy and the first late-stage phase to show a clinically meaningful improvement over Keytruda alone. Melanoma, the target indication, is expected to increase by 112,000 cases by the end of the year, including an estimated 8,500 deaths, after some 330,000 cases were diagnosed globally in 2022. In August, Moderna received FDA approval of its biologics license application for the 2026 to 2027 formulas of its Spikevax and mNEXSPIKE COVID-19 vaccines. The vaccine maker is set to join the Nasdaq 100 index on Friday, October 9, replacing Warner Bros. Discovery Inc., which is set to merge with Paramount Skydance Corp. on Tuesday, October 6.

Impact on assets 5

Biotech & Genomic Medicine▲ · 2 stocks
Moderna Inc
MRNA
▲ PositiveTechnologyRegulationrelevance

Its mRNA cancer therapy Intismeran Autogene with Keytruda achieved the primary endpoint in a phase 3 trial, driving the stock's 175% Q3 surge.

Merck & Company Inc
MRK
▲ PositiveTechnologyrelevance

Moderna's Intismeran Autogene combined with Merck's Keytruda hit the primary endpoint of recurrence-free survival in a late-stage cancer trial, a positive readout for Keytruda's use in combination therapy.

Communication Services▲ · 2 stocks
Warner Bros Discovery Inc
WBD
± Mixedrelevance

Named only as the company being replaced in the Nasdaq 100 by Moderna ahead of its merger with Paramount Skydance; no substantive development affecting it.

Critical Materials & Supply Chain▲ · 1 stocks
© 2026 MarketIVNews